Clinical Study for Cats with Mammary Cancer - Information for referring veterinarians

Why refer your patients?

• The therapy (GCN2-IN-6) has been carefully tested in preclinical studies and is well-tolerated.
• Your referred patients will receive standard surgical care plus the investigational therapy.
• Participation contributes valuable data for advancing cancer treatments in both cats and humans.

Study design highlights

• Neo-adjuvant and adjuvant therapy administered around the time of mastectomy.

• Safety and efficacy are continuously monitored.

• Feline mammary adenocarcinoma is a validated model for TNBC research.

Referral process

• Eligible cats: cats diagnosed with mammary tumors, eligible for surgery.

• As referring veterinarians, you can retain primary responsibility for routine care; the study team coordinates treatment administration and follow-up.

• Participation is voluntary, and owners can withdraw at any time.

Impact:

By referring cats to this study, you are helping advance cutting-edge cancer research, improve therapeutic options, and potentially enhance outcomes for both feline and human patients.

Contact

Further information can be obtained by mailing Ada Krupa (adriana.krupa@ugent.be) or Hilde de Rooster (hilde.derooster@ugent.be) or by phone (+32 9 264 77 00).